http://www.reportbuyer.com/rss.htmlWelcome to the Research & Development sector within Pharma & Healthcare. In this segment you will find reports on Clinical Trials and Company Pipeline reports.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/research_r_d/nanobiotechnology.htmlNanotechnology is the creation and utilization of materials, devices, and systems through the control of matter on the nanometer-length scale (a nanometer is one billionth of a meter. Nanobiotechnology, an integration of physical sciences, molecular engineering, biology, chemistry and biotechnology holds considerable promise of advances in pharmaceuticals and healthcare. The report starts with an introduction to various techniques and materials that are relevant to nanobiotechnology. cd4f89cc1d1a5c615c7a73daeca382dbSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/neuroprotection.htmlThis report describes the role of neuroprotection in acute disorders such as stroke and injuries of the nervous system as well as in chronic diseases such as neurodegenerative disorders because many of the underlying mechanisms of damage to neural tissues are similar in all these conditions and several products are used in more than one disorder. Over 500 products have been investigated for neuroprotective effects including those from the categories of free radical scavengers, anti-excitotoxic agents, apoptosis (programmed cell death) inhibitors, anti-inflammatory agents, neurotrophic factors, metal ion chelators, ion channel modulators and gene therapy. Some of the agents are old established pharmaceuticals whereas others are new biotechnology products. b87656a1ca389949795c13ac2d2dc25bSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/innovative_drug_rad_china_1.htmlAs Chinese pharmaceutical industry is rising rapidly, a growing number of Chinese drug companies pay attention to investing in research of innovative medicines. Their attempts are encouraged by government who promises to provide financial support and improve industry infrastructure. Their programs are infused with increasing numbers of returnees. e171e451d9df015ebb3eb71d52f4eaedSat, 10 Oct 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/generics_growth_strategies.htmlThe last three years has seen several major shifts in generics company strategies. From 2006 to 2008 a period of high M&A activity was seen as many companies sought to expand geographically and create the scale required to compete with large pharmaceutical companies. Since the global financial crisis the level of deals has declined due to the implications of restricted debt markets and the need to reduce company debt. a2cb3e3b90b25f772c8becf44e1721c9Wed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/booming_clinical_trials_market_india.htmlThe clinical trial market in India looks very lucrative. The country promises to be one of the hottest destinations for conducting global clinical trials, owing to a huge patient pool representing both chronic and infectious diseases, easy recruitment of patients, and high cost savings. Moreover, the market is getting boost from improved IPR protection with changed rules and also from reduced taxes and duties. ca509dd2fc6ee9ebd81cdcdd72600e42Wed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/future_biodefense_industry.htmlThe major contemporary bioterrorist event which has opened up programs of research and development (R&D) in pharmaceutical countermeasures and treatments was the anthrax mail attacks which occurred only weeks after the 9/11 atrocities, in October 2001. The mailings killed five people and exposed hundreds more ??. 5b63d40a0270b3c7373ae296aaa7d27cWed, 09 Sep 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/leading_pharmaceutical_companies_rd_expenditures_major_programs.htmlFor each company, the report provides: Annual R&D budget. Research facilities and staff. New technologies, drugs, and indications in development, including their phase and anticipated introduction dates. 7986e98afb848301443d34de90f9df73Tue, 01 Sep 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/medical_research_china.htmlThe IBISWorld Medical Research in China industry report comprises establishments that are mainly engaged in basic research, applied research and development activities in the medical field and pharmaceutical field. Establishments in the industry include laboratories of medical research institutes, medical schools, and biotechnology companies. The following research functions are not included in this industry: (1) Research and development activities conducted by enterprises in the pharmaceutical or medical equipment manufacturing industries; (2) Biological research unrelated to the human body or human diseases; (3) Veterinary medical research; and, (4) The commercialization of medical or pharmaceutical research. f835c289d9eae84c1ec7956101bf3146Sat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/clinical_laboratory_testing_market_report_2009_edition.htmlClinical Laboratory testing market, also called the diagnostic testing market in broader terms, includes all the medical tests done at the laboratories. Laboratory testing forms the basis for most of the decisions in diagnosis, treatment, and prognosis. There has been a notable shift away from traditional, fee-for-service medicine to managed-cost health care, bringing about many market-based changes in the clinical laboratory market. 27d465a3866527e9c9184a2d3e31b9aeSat, 08 Aug 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/bioarrays_life_science_research_diagnostics_drug_rad.htmlThis research report is about the worldwide bioarray tools, technologies and services market.   Bioarrays are also known as DNA microarrays, protein arrays, or biochips. These key mainstream life science research products and services involve technologies that scientists use to detect and analyze genetic and protein material such as DNA, RNA, proteins, antibodies, stem cells, tissues, biomarkers and so on. a50ba8d6e4cc835e69774ca3cf0e13c2Sat, 01 Aug 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/parexels_bio_pharma_rad_statistical_sourcebook_1.htmlNow industry's most widely read reference on emerging pharma/biotech R&D trends worldwide, PAREXEL's Pharmaceutical R&D Statistical Sourcebook 2009/2010 features hundreds of all-new, real-world studies, analyses, articles, and data sets providing fresh insights into the developments reshaping pharma R&D and the industry itself. New proprietary analyses on US clinical trial starts, now segmented for the first time by therapeutic category, as well as overall active clinical trials, also segmented by therapeutic category. See how quickly the numbers of active clinical trials are growing, and precisely which therapeutic areas are driving this growth. 77cb45b01f3e6fa7336bfd0a15e37596Thu, 16 Jul 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/clinical_trials_world_market_2009_2024.htmlOur New Report Shows You How this Sector Will Expand its Revenues and Influence, Highlighting the Opportunities from 2009 Onwards The market for clinical trials has been expanding rapidly in recent years, with impressive revenue growth and important trends. One regional market expanded by 65% in 2008. From the perspectives of various pharma stakeholders, the expanding clinical research market represents opportunities for revenue growth and cost savings. d9fad0a7aa319a6dba5e49e3aeb5ad9dTue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/clinical_trials_market_india.htmlIndia is fast emerging as the most preferred destination for clinical trials. Clinical trial is the final step in drug development process after preliminary laboratory research and animal testing. The process of drug discovery is quite long and expensive and trials for any drug are usually conducted in phases which might last for many years. 114da971b5a11d4522dd407b2a588ec3Tue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/clinical_immunoanalyzer_markets.htmlClinical immunoanalyzer analysis is one of the most important functions of clinical laboratory analysis. By all accounts, automated immunoassay testing is the most rapidly developing of the traditional clinical laboratory sectors. Clinical immunoanalyzer analysis usually refers to determining the concentration or activity of protein, carbohydrate, lipid, enzyme or small molecule in easily collected body fluids, such as blood, serum, plasma or urine. a86ef9c550e8f75619c79b97a23414f8Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/clinical_chemistry_analyzers.htmlClinical chemistry analysis is one of the most important areas within clinical laboratory analysis. The term clinical chemistry usually refers to determining the concentration or activity of a protein, carbohydrate, lipid, electrolyte, enzyme or small molecule in easily-collected bodily fluids such as blood, serum, plasma or urine. However, it is not necessarily limited to these determinations. 70bf77346354e4a35e82c21b456ba38cSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/emerging_clinical_trial_locations_latin_america.htmlOver the last decade pharmaceutical and biotechnology companies have entered a period where they have become confronted by a variety of complex issues affecting their operational efficiency and profitability. It has now become generally acknowledged that the current business models have become both economically unsustainable and operationally unsuited to act quickly enough to produce the types of innovative treatments that will be demanded by global markets. Major issues confronting both the pharmaceutical and biotechnology market are: the requirement to reduce the escalating costs and risks associated with drug development; and reduce clinical trial timelines by improving patient recruitment and improving the efficiency of clinical trial results analysis and reporting. 52b62f6d1c99bef00d65f10af32b9813Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/world_medical_markets_fact_book_2009.htmlEssential facts, figures, forecasts and statistics on medical markets around the world. In today's challenging market environment the need to understand world medical marketplaces, and be able to answer quickly those questions that arise daily, is essential. Therefore an authoritative, current and comprehensive market intelligence source is an invaluable aid for every executive. 451617ce59a797fb569f741e1da07989Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/emerging_clinical_trial_locations_india.htmlOver the last decade pharmaceutical and biotechnology companies have entered a period where they have become confronted by a variety of complex issues affecting their operational efficiency and profitability. It has now become generally acknowledged that the current business models have become both economically unsustainable and operationally unsuited to act quickly enough to produce the types of innovative treatments that will be demanded by global markets. Major issues confronting both the pharmaceutical and biotechnology market are: the requirement to reduce the escalating costs and risks associated with drug development; and reduce clinical trial timelines by improving patient recruitment and improving the efficiency of clinical trial results analysis and reporting. 0c5ed1bbeb8a637d0c9e2a477d39770aSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/clinical_trials/emerging_clinical_trial_locations_eastern_europe.htmlOver the last decade pharmaceutical and biotechnology companies have entered a period where they have become confronted by a variety of complex issues affecting their operational efficiency and profitability. It has now become generally acknowledged that the current business models have become both economically unsustainable and operationally unsuited to act quickly enough to produce the types of innovative treatments that will be demanded by global markets. Major issues confronting both the pharmaceutical and biotechnology market are: the requirement to reduce the escalating costs and risks associated with drug development; and reduce clinical trial timelines by improving patient recruitment and improving the efficiency of clinical trial results analysis and reporting. a7fb2a16b88aba711929a7b558736cf7Sat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)http://www.reportbuyer.com/pharma_healthcare/research_r_d/accelerating_lead_generation.htmlAccelerating Lead Generation Emerging technologies and strategies Report Overview The number of approvals for new drugs and biologics has fallen steadily in recent years, despite increasing R&D expenditure. Cost effective and innovative approaches to drug discovery and development have therefore become particularly important to ensure shareholder value. Improvements to the lead generation process are a key initiative for company's aiming to avoid expensive compound failures in the latter stages of the drug discovery process. 3c341263fc8a0a300909aef501ed550bSat, 06 Jun 2009 12:00:00 GBPharma & Healthcare/Research (R&D)